(thirdQuint)A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.

1% or Benzoyl Peroxide Gel 4%.

 This is a 3 arm, 12-week, randomized, double-blind, multicenter study comparing safety and efficacy of DTG 5% twice daily plus vehicle control once daily vs.

 DTG 5% twice daily plus adapalene gel 0.

1% once daily vs.

 DTG 5% twice daily plus 4% benzoyl peroxide gel once daily in subjects with acne vulgaris.

 Approximately 300 male and female subjects, 12 years of age and older, with acne vulgaris and > 20 inflammatory lesions (papules and/or pustules) and > 20 non-inflammatory lesions (comedones) above the mandibular line at Baseline will be enrolled.

 Follow-up visits will occur at Week 2, 4, 8 and 12.

 Global Acne Assessments, Lesion Counts and Local Adverse Reaction Assessments will be conducted at each visit.

 A physical exam will be done at Baseline and Week 12.

 Plasma Dapsone Level samples will be drawn at Baseline, Week 2 and Week 12/ET for dapsone plasma level assessments.

 Adverse events and concomitant medications will be assessed throughout the study.

.

 A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.

1% or Benzoyl Peroxide Gel 4%@highlight

The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.

1% or benzoyl peroxide gel 4%.

 The second objective of the study is to determine dapsone exposure after co-administration of DTG 5% with vehicle control, adapalene or benzoyl peroxide gel.

